Analysts project that Yorvipath could fully replace conventional therapy in 95% of patients based on its Phase 3 trial results. The expectation is that all previous Natpara-experienced patients will switch to Yorvipath. This transition is anticipated to drive significant revenue growth for Ascendis Pharma in the coming years. InvestingPro data reveals impressive gross profit margins of 87.83%, indicating strong pricing power and efficient production costs. The company has already demonstrated strong revenue growth of 36.34% over the last twelve months.